Zoetis announced the launch of DRAXXIN® 25 (tulathromycin injection) Injectable Solution, a lower concentration of DRAXXIN® (tulathromycin) Injectable Solution, to treat bovine respiratory disease (BRD) in suckling, dairy and veal calves.

Just like the current concentration of DRAXXIN, DRAXXIN 25 offers broad-spectrum coverage against the major causes of BRD, including Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis. However, producers and veterinarians should note that DRAXXIN 25 has a pre-slaughter withdrawal time of 22 days, compared with the 18-day pre-slaughter time for DRAXXIN.

“The efficacy of DRAXXIN has made it a leading choice by veterinarians and producers for the treatment of BRD in larger, ruminating calves,” said Dr. Robert Lynch, senior veterinarian, Dairy Technical Services, Zoetis. “The new formulation of DRAXXIN 25 allows for more-accurate and convenient dosing for smaller calves. Producers and veterinarians can be confident they are administering the correct treatment needed.”

Zoetis also announced the approval of DRAXXIN for the treatment against the major causes of BRD associated with M. haemolytica, P. multocida, H. somni and M. bovis in suckling, dairy and veal calves. Previously, DRAXXIN was approved only for use in nonlactating dairy cattle (cattle younger than 20 months of age, including dairy calves) and beef cattle.

“Through Zoetis’s efforts to obtain FDA approval to remove the veal calf restriction and include suckling calves in the DRAXXIN label, veterinarians can prescribe DRAXXIN with confidence and producers can practice responsible antibiotic use while treating BRD symptoms with a demonstrated and effective BRD treatment option for veal calves,” said Dr. Lynch.